Visas open door to increased US FDA drug inspections in China
This article was originally published in Scrip
China's decision to finally grant visas to enable an increase in the number of US FDA drug inspectors stationed in the country apparently marks a willingness to open up its pharmaceutical manufacturing activities to wider outside scrutiny.
You may also be interested in...
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.